Stuart J Moat

Summary

Affiliation: Cardiff University
Country: UK

Publications

  1. ncbi Folate augmentation of treatment - evaluation for depression (FolATED): protocol of a randomised controlled trial
    Seren Haf Roberts
    North Wales Section of Psychological Medicine, Institute of Medical and Social Care Research IMSCaR, Bangor University, Academic Unit, Wrexham Technology Park, Wrexham, LL13 7YP, UK
    BMC Psychiatry 7:65. 2007
  2. ncbi Folate, homocysteine, endothelial function and cardiovascular disease
    Stuart J Moat
    Cardiovascular Sciences Research Group, Wales Heart Research Institute, University of Wales College of Medicine, Cardiff, UK
    J Nutr Biochem 15:64-79. 2004
  3. ncbi Effect of riboflavin status on the homocysteine-lowering effect of folate in relation to the MTHFR (C677T) genotype
    Stuart J Moat
    Cardiovascular Sciences Research Group, Wales Heart Research Institute, University of Wales College of Medicine, Cardiff, Wales CF14 4XN, United Kingdom
    Clin Chem 49:295-302. 2003
  4. ncbi Methylenetetrahydrofolate reductase 677C-->T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial
    Pauline A L Ashfield-Watt
    Cardiovascular Sciences Research Group, Wales Heart Research Institute, University of Wales College of Medicine, Cardiff, Wales, United Kingdom
    Am J Clin Nutr 76:180-6. 2002
  5. ncbi Differential effects of low and high dose folic acid on endothelial dysfunction in a murine model of mild hyperhomocysteinaemia
    Zoe L Clarke
    Wales Heart Research Institute, Wales College of Medicine, Cardiff University, Heath Park Campus, Cardiff, CF14 4XN, United Kingdom
    Eur J Pharmacol 551:92-7. 2006
  6. ncbi Short-term high-dose folic acid does not alter markers of endothelial cell damage in patients with coronary heart disease
    Sagar N Doshi
    Cardiovascular Sciences Research Group, Department of Pharmacology, Wales Heart Research Institute, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, UK
    Int J Cardiol 94:203-7. 2004
  7. ncbi Folic acid reverses endothelial dysfunction induced by inhibition of tetrahydrobiopterin biosynthesis
    Stuart J Moat
    Department of Medical Biochemistry, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, United Kingdom
    Eur J Pharmacol 530:250-8. 2006
  8. ncbi Homocysteine and endothelial function in human studies
    Stuart J Moat
    Department of Medical Biochemistry and Immunology, Wales College of Medicine, Cardiff University and the University Hospital of Wales, Cardiff, United Kingdom
    Semin Vasc Med 5:172-82. 2005
  9. ncbi Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering
    Sagar N Doshi
    Cardiovascular Sciences Research Group, Wales Heart Research Institute, Department of Pharmacology, University of Wales College of Medicine, Heath Park, Cardiff, UK
    Circulation 105:22-6. 2002
  10. ncbi Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease
    Cheerag Shirodaria
    Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom
    Circulation 115:2262-70. 2007

Collaborators

  • Robert G Newcombe
  • Michael L Burr
  • H J Powers
  • S N Doshi
  • Helga Refsum
  • M D Randall
  • K M Channon
  • Cheerag Shirodaria
  • Seren Haf Roberts
  • Zoe L Clarke
  • Martin McKee
  • Malcolm J Lewis
  • Angela Matthews
  • Pauline A L Ashfield-Watt
  • Dyfrig Hughes
  • Keith Lloyd
  • Clare Wilkinson
  • Ian Russell
  • Charalambos Antoniades
  • Ravi Pillai
  • Clare E Jackson
  • Matthew D Robson
  • David B Menkes
  • Stefan Neubauer
  • Munir Pirmohamed
  • Rhiannon Whitaker
  • Gary Slegg
  • Emma Bedson
  • Jane M Francis
  • Chandi Ratnatunga
  • Justin Lee
  • Johannes Thome
  • Richard Tranter
  • Derek Lang
  • Alastair L Miller
  • Ian McDowell
  • James R Bonham
  • Amin Rostami-Hodjegan
  • Anupam Chakrapani
  • Jane M Whiting
  • Geoffrey T Tucker
  • J Edward Wraith
  • Catherine H Pullin
  • Trevor N Johnson
  • Zoë E Clark
  • Ian F W McDowell

Detail Information

Publications16

  1. ncbi Folate augmentation of treatment - evaluation for depression (FolATED): protocol of a randomised controlled trial
    Seren Haf Roberts
    North Wales Section of Psychological Medicine, Institute of Medical and Social Care Research IMSCaR, Bangor University, Academic Unit, Wrexham Technology Park, Wrexham, LL13 7YP, UK
    BMC Psychiatry 7:65. 2007
    ....
  2. ncbi Folate, homocysteine, endothelial function and cardiovascular disease
    Stuart J Moat
    Cardiovascular Sciences Research Group, Wales Heart Research Institute, University of Wales College of Medicine, Cardiff, UK
    J Nutr Biochem 15:64-79. 2004
    ..The potential beneficial role of folic acid supplements on vascular disease are currently being tested in randomized placebo controlled studies...
  3. ncbi Effect of riboflavin status on the homocysteine-lowering effect of folate in relation to the MTHFR (C677T) genotype
    Stuart J Moat
    Cardiovascular Sciences Research Group, Wales Heart Research Institute, University of Wales College of Medicine, Cardiff, Wales CF14 4XN, United Kingdom
    Clin Chem 49:295-302. 2003
    ..It has been proposed that riboflavin may act together with folate to lower plasma tHcy, particularly in individuals with the thermolabile MTHFR T variant...
  4. ncbi Methylenetetrahydrofolate reductase 677C-->T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial
    Pauline A L Ashfield-Watt
    Cardiovascular Sciences Research Group, Wales Heart Research Institute, University of Wales College of Medicine, Cardiff, Wales, United Kingdom
    Am J Clin Nutr 76:180-6. 2002
    ..Low folate status and elevated plasma homocysteine are associated with increased risk of neural tube defects and cardiovascular disease. Homocysteine responses to folate may be influenced by genetic variants in folate metabolism...
  5. ncbi Differential effects of low and high dose folic acid on endothelial dysfunction in a murine model of mild hyperhomocysteinaemia
    Zoe L Clarke
    Wales Heart Research Institute, Wales College of Medicine, Cardiff University, Heath Park Campus, Cardiff, CF14 4XN, United Kingdom
    Eur J Pharmacol 551:92-7. 2006
    ..While low dose folic acid may restore this response in a homocysteine-dependent manner, the higher dose has an additional effect on nitric oxide-mediated relaxation that would appear to be independent of homocysteine lowering...
  6. ncbi Short-term high-dose folic acid does not alter markers of endothelial cell damage in patients with coronary heart disease
    Sagar N Doshi
    Cardiovascular Sciences Research Group, Department of Pharmacology, Wales Heart Research Institute, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, UK
    Int J Cardiol 94:203-7. 2004
    ....
  7. ncbi Folic acid reverses endothelial dysfunction induced by inhibition of tetrahydrobiopterin biosynthesis
    Stuart J Moat
    Department of Medical Biochemistry, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, United Kingdom
    Eur J Pharmacol 530:250-8. 2006
    ..This study demonstrates that folic acid reverses the endothelial dysfunction induced by BH4 depletion independently of either the regeneration or stabilization of BH4 or an antioxidant effect...
  8. ncbi Homocysteine and endothelial function in human studies
    Stuart J Moat
    Department of Medical Biochemistry and Immunology, Wales College of Medicine, Cardiff University and the University Hospital of Wales, Cardiff, United Kingdom
    Semin Vasc Med 5:172-82. 2005
    ..However, changes in FMD may not translate into vascular endpoints, and the outcomes of clinical intervention trials with different doses of folic acid are awaited with interest...
  9. ncbi Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering
    Sagar N Doshi
    Cardiovascular Sciences Research Group, Wales Heart Research Institute, Department of Pharmacology, University of Wales College of Medicine, Heath Park, Cardiff, UK
    Circulation 105:22-6. 2002
    ..02). FMD improvement did not correlate with reductions in either fHcy or tHcy at any time. CONCLUSIONS: These data suggest that folic acid improves endothelial function in CAD acutely by a mechanism largely independent of homocysteine...
  10. ncbi Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease
    Cheerag Shirodaria
    Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom
    Circulation 115:2262-70. 2007
    ..We compared the effects of folic acid on human vessels using pharmacological high-dose versus low-dose treatment, equivalent to dietary folate fortification...
  11. ncbi Plasma total homocysteine: instigator or indicator of cardiovascular disease?
    Stuart J Moat
    Department of Medical Biochemistry and Immunology, University Hospital of Wales and Wales College of Medicine, Heath Park, Cardiff CF14 4XW, UK
    Ann Clin Biochem 45:345-8. 2008
    ..This lack of effect of tHcy lowering strongly suggests that homocysteine is not an instigator but merely an indicator of CVD...
  12. ncbi Treatment of coronary heart disease with folic acid: is there a future?
    Stuart J Moat
    Am J Physiol Heart Circ Physiol 287:H1-7. 2004
  13. ncbi Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us?
    Sagar N Doshi
    Cardiovascular Institute, Mount Sinai School of Medicine, New York, USA
    Atherosclerosis 165:1-3. 2002
  14. ncbi Letter by Powers et al regarding article, "Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C-->T polymorphism"
    Hilary J Powers
    Circulation 114:e65; author reply e66. 2006
  15. ncbi An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria
    Angela Matthews
    Department of Chemical Pathology and Neonatal Screening, Sheffield Children's Hospital, Manchester, UK
    Br J Clin Pharmacol 54:140-6. 2002
    ..CONCLUSIONS: PK-PD modelling allows recommendations for optimal dosage of betaine in the treatment of homocystinuria, that have the potential for improved patient compliance and both therapeutic and pharmacoeconomic benefit...
  16. ncbi Statins and micronutrients: unanswered questions
    Martin McKee
    J R Soc Med 97:459-60. 2004